Drug-resistant bacteria can infect anyone.
It’s why antibiotic resistance is one of the biggest
threats to global health.
The issue of AMR* explained
The discovery of antibiotics transformed our world by making previously incurable illnesses treatable and allowing medical procedures like operations and chemotherapy to be performed safely. Millions of lives have been saved and our well-being radically improved.
Partnerships are at the heart of our success in developing new and improved treatments. GARDP is currently working with more than 60 partners in 22 countries.
“Tackling the threat of drug resistant infections requires an urgent and truly global response. Critical to achieving this is GARDP’s public-private partnership approach and commitment to ensuring new and improved antibiotics are available for every person who needs them, wherever they live”
HOW WE DO IT
Our work is focused on treatments for drug-resistant bacterial infections identified by the World Health Organization as being in most urgent need of new drugs. Our research and development efforts also prioritize people disproportionately affected by drug resistance, including babies, children and hospitalized people.
To do this we’re working on research and development projects with more than 60 partners in 22 countries, including in North America. For example, we’re partnering with US-based biotech Entasis Therapeutics on the development of a new antibiotic active resistant strains of gonorrhea, including sponsoring a phase 3 trial of this drug in the US, Netherlands, Thailand and South Africa.
Take action now. Fund our Mission.
Partnerships are at the heart of our success in developing new and improved treatments. GARDP is currently working with more than 60 partners in 22 countries.
Serious bacterial infections
GARDP’s discovery and exploratory programme focuses on three activities to advance antibiotic R&D – discovery and exploratory research.
Partnerships are at the heart of our success in developing new and improved treatments. GARDP is currently working with more than 60 partners in 22 countries.
Publications
Addressing AMR for better care in cancer patients – by Yehoda M. Martei and Shalini J. Zürn
. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quod autem satis est, eo quicquid accessi.
Read moreNo settings found for the grid #1.